Search 

HealthCare Royalty Partners is a global healthcare investment firm with $1.5 billion in assets under management. Launched in 2007 by Founding Managing Directors Gregory B. Brown, M.D., Todd C. Davis and Clarke B. Futch, HC Royalty specializes in making structured investments in commercial-stage healthcare companies and products. Our deep experience, broad and flexible investment platform and proven track record set HC Royalty apart from other firms.

We closed on our first fund, HealthCare Royalty Partners, L.P., in July 2008 with over $500 million in capital. At closing this represented one of the largest inaugural healthcare-focused funds ever raised. In December 2011, we closed the largest private equity fund dedicated to healthcare royalty investments, HealthCare Royalty Partners II, L.P. and an affiliated fund, with $1 billion in capital. Our world-class list of investors consists of public and corporate pension funds, financial institutions, insurance companies, funds-of-funds and university endowments.

Our broad-based internal team has deep investment skills, as well as financial, legal and operational expertise. Collectively, these individuals possess over 100 years of healthcare and financial experience specifically in principal investing, structured finance, healthcare industry senior management, Wall Street research, healthcare industry consulting, and scientific and clinical advisory work

Founded in 2007, HealthCare Royalty Partners is a global healthcare investment firm with over USD 1.5 billion of capital under management. The Firm specializes in structured financing solutions for the life sciences industry.

The Company is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company has two FDA approved products: DUEXIS® and RAYOS®.  DUEXIS®s is a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill.  DUEXIS is indicated for the relief of signs and symptoms of rheumatoid arthritis (“RA”) and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications. In June 2012, the Company began expanding its commercial organization and expects to almost double its original field force size by the end of the third quarter of 2012, to approximately 150 field sales representatives. Also in June 2012, the Company engaged Mallinckrodt LLC, the pharmaceutical business of Covidien plc, on a non-exclusive basis to co-promote DUEXIS in the U.S. and entered into an exclusive collaboration, license and supply agreement with Grünenthal S.A. for the potential commercialization of DUEXIS in Latin America.

The Company’s second product, RAYOS®, known as LODOTRA® outside the U.S., is a proprietary delayed release formulation of low-dose prednisone that is currently marketed in Europe by its distribution partner, Mundipharma International Corporation Limited (“Mundipharma”), for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. In addition, the Company has granted to Mundipharma commercialization rights to LODOTRA in Asia and Latin America. On July 26, 2012, the FDA approved RAYOS for the treatment of a broad range of diseases, including RA, polymyalgia rheumatica (“PMR”), psoriatic arthritis (“PsA”), ankylosing spondylitis (“AS”), asthma and chronic obstructive pulmonary disease (“COPD”). The Company anticipates the launch of RAYOS in the United States in the fourth quarter of 2012. The Company’s strategy is to commercialize its products in the U.S. and to enter into licensing or additional distribution agreements for commercialization of its products outside the U.S.